Growth Metrics

Nektar Therapeutics (NKTR) Equity Income (2025)

Nektar Therapeutics has reported Equity Income over the past 1 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly results put Equity Income at -$1.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$8.7 million (changed N/A YoY), and the annual figure for FY2025 was -$8.7 million, changed.
  • Equity Income for Q4 2025 was -$1.3 million at Nektar Therapeutics, down from -$534000.0 in the prior quarter.
  • Over the last five years, Equity Income for NKTR hit a ceiling of -$534000.0 in Q3 2025 and a floor of -$4.5 million in Q1 2025.